Omacetaxine mepesuccinate is under clinical development by Teva Pharmaceutical Industries and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Omacetaxine mepesuccinate’s likelihood of approval (LoA) and phase transition for Myelodysplastic Syndrome took place on 14 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 14 Sep 2022 increased Omacetaxine mepesuccinate’s LoA and PTSR for Refractory Acute Myeloid Leukemia, and increased LoA and PTSR for Relapsed Acute Myeloid Leukemia.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Omacetaxine mepesuccinate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Omacetaxine mepesuccinate overview

Omacetaxine mepesuccinate (Homoharringtonine, Omapro, Synribo, Tekinex, CGX635) is an antineoplastic agent. It is formulated as injection, administered by subcutaneous route. It is indicated for the treatment of chronic myelocytic Leukemia.

The drug candidate is also under development for the treatment of myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. It was also under development for the treatment of Philadelphia chromosome-positive (Ph+), acute promyelocytic leukemia (APL), acute myelocytic leukemia (AML), solid tumors including breast cancer, lung cancer, head and neck cancer, colorectal cancer, melanoma and sarcoma.

Teva Pharmaceutical Industries overview

Teva Pharmaceutical Industries (Teva) discovers, develops, manufactures, and commercializes generic and specialty medicines. The company provides specialty medicines to treat disorders of the central nervous system (CNS), respiratory, dermatology, cancer, women’s health, and other disease conditions. It offers generic medicines in a range of dosage forms including capsules, tablets, injectables, liquids, inhalants, creams, and ointments. Teva also provides over-the-counter (OTC) products, besides active pharmaceutical ingredients (APIs). It focuses on developing new generic drugs. The company conducts its worldwide operations through a network of subsidiaries in regions such as North America, Europe, and International Markets. Teva is headquartered in Tel Aviv, Israel.

Quick View Omacetaxine mepesuccinate LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Omacetaxine mepesuccinate
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.